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BACKGROUND: IGFBP-3 is a multifunctional protein that inhibits growth and induces apoptosis of cancer cells.
Hypermethylation of the promoter represses expression of the IGFBP-3 gene. We undertook this study to assess
the impact of IGFBP-3 methylation on survival of early stage gastric cancer patients. METHODS: Of the 482 tissue
samples from gastric cancer patients who underwent curative surgery, IGFBP-3 methylation was tested in 138
patients with stage IB/II gastric cancer. We also analyzed IGFBP-3 methylation in 26 gastric cancer cell lines.
IGFBP-3 methylation was evaluated by methylation-specific polymerase chain reaction (MethyLight). Statistical
analyses, all two-sided, were performed to investigate the prognostic effects of methylation status of the IGFBP-3
promoter on various clinical parameters. RESULTS: Hypermethylation of IGFBP-3 was observed in 26 (19%) of the
138 stage IB/II gastric cancer patients. Clinicopathological factors such as age, Lauren classification, sex, tumor
infiltration, lymph node metastasis, and histologic grade did not show a statistically significant association with the
methylation status of the IGFBP-3 promoter. Patients with a hypermethylated IGFBP-3 promoter had similar 8-year
disease-free survival compared with those without a hypermethylated IGFBP-3 promoter (73% vs 75%, P= .78). In
subgroup analyses, females, but not males, seemed to have poorer prognosis for DFS and OS in the subset of
patients with IGFBP-3 methylation as compared with those without IGFBP-3 methylation (8-year DFS: 55.6% vs
71.6%, P = .3694 and 8-year overall survival: 55.6% vs 68.4%, P = .491, respectively) even with no statistical
significance. CONCLUSIONS: The status of IGFBP-3 methylation as measured by methylation-specific polymerase
chain reaction proposed the modest role for predicting survival in specific subgroups of patients with early-stage
gastric cancer who undergo curative surgery. However, this needs further investigation.
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Gastric cancer is the leading cause of cancer death worldwide, with an
incidence of 18.9 of 100,000 per year [1]. The incidence of gastric
cancer is estimated to be 934,000 cases, with 56% of new cases
occurring in East Asia [2]. According to the Central Tumor Registry
data for 2002, gastric cancer accounts for 20.8% of all cancers in
Korea [3]. Although the overall survival (OS) of gastric cancer has
been improved owing to the application of a national fiber optic
esophagogastroduodenoscopy screening program in adults older than
40 years in Korea, a large proportion of patients are still diagnosed at
the metastatic stage. The median survival time following cytotoxic
chemotherapy is still less than 1 year; and thus metastatic gastric
cancer remains a therapeutic challenge for medical oncologists [1].
The role of molecularly targeted therapy has not been adequately
explored in gastric cancer compared with other common solid tumors
such as breast, colorectal, or non–small cell lung cancer.
Insulin-like growth factors (IGF-I and -II) and their receptors play
a pivotal role in regulating cell proliferation, differentiation, and
apoptosis [4]. Aberrant expression and regulation of these proteins
have been implicated in the development and prognosis of many
human cancers [5,6]. There are at least six IGF-binding proteins
(IGFBPs). IGFBP-3 is the most abundant IGFBP found in serum
and binds the majority of serum IGFs [7]. IGFBP-3 regulates IGF
bioactivity by sequestering IGF in the extracellular milieu, thereby
inhibiting its mitogenic and antiapoptotic actions. In addition to its
IGF-dependent function, IGFBP-3 also has IGF-independent
antiproliferative and proapoptotic effects that seem to involve cell
surface receptors for IGFBP-3 [4,8–11]. IGFBP-3 is expressed in
most human tissue and in a variety of cell lines, including those of
gastric origin [12,13]. Studies of gastric cancer cell lines have shown
that IGFBP-3 can markedly inhibit the response of gastric cancer cells
to IGF [12]. A recent study also reported that IGFBP-3 is protective
against the development of gastric carcinoma by preventing the
formation of intestinal metaplasia, and improves the prognosis of
gastric cancer [6].
The integral role of epigenetic mechanisms such as promoter
hypermethylation of tumor suppressor genes has become ever more
apparent over the past decade [14]. Promoter hypermethylation is
widespread in some cancers, occurs in the early stages of cancer
development, and has been correlated with clinicopathologic features
indicative of a poor prognosis, thus indicating the potential of gene
hypermethylation as a marker of clinically significant disease [15].
Promoter hypermethylation has been proposed as a mechanism for
the transcriptional silencing of IGFBP-3 in hepatocellular carcinomas
[16], early-stage non–small cell lung cancer [17], prostate cancer
[18,19], and in cancers of the bladder and ovary [20,21].
We undertook this study to assess the impact of IGFBP-3
methylation on survival of early-stage gastric cancer patients.
Statistical analysis was performed to investigate the correlations
between methylation and clinical and pathologic parameters.
Methods
Patients and Tissues
We previously reported the outcomes of 544 stage II to IV (M0)
gastric cancer patients who received adjuvant chemoradiation therapy
after curative surgery [22]. All patients were Korean and were staged
by American Joint Committee on Cancer sixth edition. The
postoperative adjuvant treatment adopted was the same as that usedfor the INT-0116 (SWOG-9008) trial, the results of which were
previously reported [23]. Between these patients and an additional 23
stage IB patients who were included in our previous study,
formalin-fixed, paraffin-embedded primary tumor tissues were
available from 482 patients. All patients provided written informed
consent according to institutional guidelines, and the study was
approved by the Institutional Review Board. Among 482 patients,
138 stage IB/II gastric cancer patients were analyzed in this study.
Gastric Cancer Cell Lines
Human gastric carcinoma cells AGS, KATO-III, MKN-1,
MKN-28, MKN-45, MKN-74, N87, SNU-1, SNU-5, SNU-16,
SNU-216, SNU-484, SNU-601, SNU-620, SNU-638, SNU-668,
and SNU-719 were purchased from the Korean Cell Line Bank
(Seoul, Korea). YCC-1, YCC2, YCC-3, and YCC-7 were kindly
provided by Dr. Hyun Cheol Chung (Yonsei Cancer Center, Seoul,
Korea). OCUM-2M was kindly provided by Dr. Masakazu Yashiro
(Osaka City University, Osaka, Japan). YCC-1, YCC-2, YCC-3, and
YCC-7 were maintained in Dulbecco’s modified Eagle’s medium
(Gibco-BRL, Carlsbad, CA) supplemented with 10% heat-
inactivated FBS, 100 U/ml penicillin, 100 U/ml streptomycin, and
2 mM glutamine. All other cell lines were cultured in RPMI-1640
medium (Gibco-BRL) supplemented with 10% heat-inactivated
FBS, 100 U/ml penicillin, 100 U/ml streptomycin, and 2 mM
glutamine. All cells were incubated in a humidified atmosphere
contained 5% CO2 at 37°C.
Bisulfite Modification
Bisulfite treatment of DNA was performed using the EpiTect
Bisulfite Kit (QIAGEN) according to manufacturer’s instructions.
Briefly, 1 μg of genomic DNA in 20 μl of water was combined with
85 μl of bisulfate mix and 35 μl of DNA protection buffer. Bisulfate
conversion of DNA was performed using the following conditions:
denaturation at 99°C for 5 minutes, incubation at 60°C for 25
minutes, denaturation at 99°C for 5 minutes, incubation at 60°C for
85 minutes, denaturation at 99°C for 5 minutes, incubation at 60°C
for 175 minutes, and hold at 20°C. The bisulfite-converted DNA was
mixed with 560 μl of Buffer BL, applied to a spin column, and
centrifuged at 12,000 rpm for 1 minute. The flow-through was
discarded and the column was washed with 500 μl of Buffer BW.
Buffer BD (500 μl) was applied to the column, which was incubated
at room temperature for 15 minutes. The column was centrifuged to
remove Buffer BD and then washed twice with Buffer BW (500 μl).
Residual Buffer BW was removed by an additional spin (12,000 rpm
for 1 minute). Buffer EB (20 μl) was added to the column to elute the
DNA. The DNA concentration was determined using a Nano-drop
spectrophotometer.
Methylation-Specific Polymerase Chain Reaction (MS-PCR)
for Quantitative DNA Methylation Analysis
The primers and probe for IGFBP-3 were as follows: IGFBP3-F,
5 -GTT TCG GGC GTG AGT ACG A-3 ; IGFBP3-R, 5 -GAA
TCG ACG CAA ACA CGA CTA C-3 ; and IGFBP3-probe,
6FAM-5 -TCG GTT GTT TAG GGC GAA GTA CGG
G-3 -TAMRA. The collagen 2A1 gene (COL2A1) was used to
normalize for the amount of input bisulfite-converted DNA. The
primers and probe for COL2A1 were as follows: COL2A1-F, 5 -TCT
AAC AAT TAT AAA CTC CAA CCA CCA A-3 ; COL2A1-R,
5 -GGG AAG ATG GGA TAG AAG GGA ATA T-3 ; and
Table 1. The Information of 23 Gastric Cell Lines Analyzed for IGFBP-3 Methylation
Status Gender Histologic Subtype Origin
Methylated IGFBP-3
KATO-III Male Poorly Pleural effusion, metastatic
OCUM-2 M Female Poorly Stomach, primary
AGS Female Poorly Stomach, primary
N87 Male Well Liver, metastatic
MKN-28 Female Moderate Lymph node, metastatic
MKN-45 Female Poorly Liver, metastatic
MKN-74 Male Moderate Liver, metastasis
SNU-16 Female Poorly Ascites, metastatic
SNU-216 Female Moderate Lymph node, metastatic
SNU-484 Male Poorly Stomach, primary
SNU-601 Male Poorly Ascites, metastatic
SNU-620 Female Poorly Ascites, metastatic
SNU-638 Male Poorly Ascites, metastatic
SNU-719 Male Moderate Stomach, primary
Un-Methylated IGFBP-3
MKN-1 Male Adenosquamous Lymph node, metastatic
YCC-1 Male NA Ascites, metastatic
YCC-2 Male NA Ascites, metastatic
YCC-3 Male NA Ascites, metastatic
YCC-7 Male NA Ascites, metastatic
SNU-1 Male Poorly Stomach, primary
SNU-5 Female Poorly Ascites, metastatic
SNU-668 Male Poorly Ascites, metastatic
290 IGFBP-3 Methylation in Gastric Cancer Kim et al. Translational Oncology Vol. 8, No. 4, 2015COL2A1-probe, VIC-5 -CCT TCA TTC TAA CCC AAT ACC
TAT CCC ACC TCT AAA-TAMRA-3 . Reactions were done in
triplicate with genomic DNA at 5 ng, primers at 900 nmol/l, probes
at 250 nmol/l, and TaqMan Universal PCR reagent under standard
thermocycling conditions. After initial denaturating for 10 minutes at
95°C, 45 cycles at 95°C for 15 seconds, 60°C for 1 minute, and 72°C
for 1 minute were carried out, followed by a final extension for
5 minutes at 72°C. AsPC-1 cell line was included as negative control
sample to compare methylation results. The percentage of methylated
reference at a specific locus was calculated by dividing the ratio of
GENE/COL2A1 template in a sample by the ratio of GENE/Figure 1. IGFBP-3 methylation as measured by MS-PCR anCOL2A1 template in SssI-treated human genomic DNA (presumably
fully methylated) and multiplying this value by 100.
DNA Extraction
One hundred thirty-eight stage IB/II gastric cancer patients were
evaluated for the methylation status of the IGFBP-3 promoter.
Fifty-four of those patients had nonneoplastic and noninfiltrated
gastric mucosa also evaluated. DNA was extracted from five 10-μm
formalin-fixed, paraffin-embedded sections containing a representa-
tive portion of each tumor block using the QIAamp DNA Mini kit
(Qiagen, Hilden, Germany). A pathologist reviewed each slide and
verified the presence of adequate tumor tissue with greater than 50%
representative malignant cells.
Statistical Analyses
Disease-free survival (DFS) was defined as the time from surgery to
the first relapse of cancer or death of any cause. Overall survival was
calculated from the date of surgery to the date of death. OS and DFS
were calculated using the Kaplan-Meier method. Correlation analyses
were performed using the two-sided χ2 test or Fisher exact test.
Differences in DFS and OS were compared using log-rank tests and
Cox proportional hazard analysis. A P value of less than .05 was
considered statistically significant.
Results
The Status of IGFBP-3Methylation in Gastric Cancer Cell Lines
IGFBP-3 methylation pattern was measured by MS-PCR in 22
known gastric cell lines (KATO-III, OCUM-2M, AGS, N87,
MKN-1, MKN-28, MKN-45, MKN-74, YCC-1, YCC-2, YCC-3,
YCC-7, SNU-1, SNU-5, SNU-16, SNU-216, SNU-484, SNU-601,
SNU-620, SNU-638, SNU-668, and SNU-719). The clinical
information of these gastric cell lines was summarized in Table 1.
In methylation analysis by MSP of IGFBP3, all gastric cell lines with
methylated band revealed IGFBP3 methylation of more than 80% in
quantitative PCR. The representative results are shown in Figure 1.d MethyLight quantitativePCR in gastric cancer cell lines.
Table 2. Clinical Features and IGFBP-3 Methylation in Stage IB/II
No. of Cases
(N = 138) (%)
IGFBP-3 Methylation
Positive
(N = 26)
Negative
(N = 112)
P Value
Age
≤60 100(72.5) 21 79 .293
N60 38 (27.5) 5 33
Lauren classification
Intestinal 56 (40.6) 8 48 .109
Diffuse 81 (58.7) 17 64
Intermediate 1 (0.7) 1 0
Sex
Male 97 (70.3) 17 80 .543
Female 41 (29.7) 9 32
Tumor infiltration
T1/T2 118 (85.5) 23 95 .766
T3/T4 20 (14.5) 3 17
Lymph node metastasis
N0/N1 135 (97.8) 26 109 1.000
N2/N3 3 (2.2) 0 3
Histologic grade (adenocarcinoma only)
Well/moderately differentiated 52 (37.7) 8 44 .419
Poorly differentiated/Other types 86 (62.3) 18 68
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The general clinical characteristics of 138 patients analyzed for the
status of IGFBP-3 methylation are presented in Table 2. The
IGFBP-3 promoter was methylated in 26 of 138 stage IB/II gastric
cancer samples. In univariate analysis, there was no statistically
significant association between the hypermethylation of IGFBP-3
and clinicopathological factors such as age, Lauren classification, sex,
tumor infiltration, lymph node metastasis, and histologic grade. The
age of 138 patients with stage IB/II gastric cancer ranged from 23 to
70 years (median, 54.5 years). Eighty-one (58.7%) of the patients
were diffuse type according to Lauren classification, and the majority
(70.3%) of patients were male.
Impact of IGFBP-3 Methylation on Recurrence and Survival
We performed survival analyses according to the methylation status
of the IGFBP-3 promoter (Figure 2). Disease recurrence was observedFigure 2. Survival analysis: Disease-free (A) and overall (B) surin 34 (24.6%) of 138 patients during the median follow-up period of
110.7 months. Stage IB/II gastric cancer patients with a hypermethy-
lated IGFBP-3 promoter had a similar DFS following curative surgery
as compared with those without IGFBP-3 methylation (5-year DFS:
73.1% vs 79.5%; IGFBP-3 methylation (+) vs IGFBP-3 methylation
(−); P = .7840). Moreover, gastric cancer patients with IGFBP-3
methylation also demonstrated similar OS following curative surgery
as compared with those without IGFBP-3 methylation (5-year OS:
80.7% vs 80.3%; IGFBP-3 methylation (+) vs IGFBP-3 methylation
(−); P = .7848). The following variables were tested using backward
stepwise Cox proportional hazards regression modeling: age (≤60 vs
N60), Lauren classification, sex (male vs female), tumor infiltration
(T1/T2 vs T3/T4), lymph node (N0/N1 vs N2/N3), histologic
grade, and the methylation status of the IGFBP-3 promoter. For DFS
and OS in all patients, none of the factors tested had a predictive role
with statistical significance at the univariate and multivariate level.
In subgroup analyses, women, but not men, showed a trend toward
poorer prognosis for DFS and OS in the subset of patients with
IGFBP-3 methylation as compared with those without IGFBP-3
methylation (8-year DFS: 55.6% vs 71.6%, P = .3694 and 8-year
OS: 55.6% vs 68.4%, P = .491, respectively; Figure 3) even with no
statistical significance.
Discussion
It has been known that the IGF-IGFBP system might play an
important role in the initiation, progression, and metastasis of gastric
cancer [6,12]. IGFBP-3, one of six members of the IGFBP family,
regulates IGF bioactivity by sequestering IGFs away from the IGF
receptor in the extracellular milieu, thereby inhibiting the mitogenic
and antiapoptotic action of IGFs [4,10]. A negative correlation
between serum IGFBP-3 levels and human cancer risk suggests a
protective role of IGFBP-3 against the effects of systemic IGFs
[24,25]. Zhang et al. [6] reported a significantly higher percentage
of positive IGFBP-3 staining in the tumor tissues of patients with
well or moderately differentiated tumors than those with poorly
differentiated tumors, indicating that IGFBP-3 may be associated
with a better prognosis.vival curves according to the status of IGFBP-3 methylation.
Figure 3. Survival analysis: Disease-free (A, B) and overall (C, D) survival curves by gender according to methylation status.
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information in mammalian cells, has profound effects on the
mammalian genome, including transcriptional repression, chromatin
structure modulation, X-chromosome inactivation, genomic imprint-
ing, and suppression of the detrimental effects of repetitive and
parasitic DNA sequence on genomic integrity [26–28]. A recent
study using a monoclonal antibody specific for 5-methylcytosine to
evaluate for the status of global DNA methylation suggests that
alteration in DNA methylation is an important epigenetic difference
in susceptibility to the development of human cancer [29]. Genomic
methylation patterns are frequently altered in tumor cells, with global
hypomethylation accompanying region-specific hypermethylation
events. CpG islands in specific regions of the promoter have been
described as a common epigenetic mechanism for the silencing of
tumor suppressor genes in cancer and as a regulator of growth in
cancers [28]. Promoter hypermethylation has been proposed as a
mechanism for transcriptional silencing of IGFBP-3 in hepatocellular
carcinoma [16], early-stage non–small cell lung cancer [17], prostatecancer [18,19], and cancers of the bladder and ovary [20,21].
Moreover, it was shown that this hypermethylation of IGFBP-3
occurs as an early event in cancer carcinogenesis. However, the role of
IGFBP-3 methylation in early-stage gastric cancer had not been
evaluated until now.
The present study is the first to assess the impact of IGFBP-3
methylation on survival in early-stage gastric cancer patients. We
found that clinicopathological factors such as age, Lauren classifica-
tion, sex, tumor infiltration, lymph node metastasis, and histologic
grade did not show a statistically significant association with the
methylation status of the IGFBP-3 promoter. In addition, no
significant difference in survival outcomes of stage IB/II gastric cancer
patients according to the status of IGFBP-3 methylation was
observed. However, this finding should be interpreted with caution.
In our study, most patients (87%), with the exception of 18 patients
with stage IB cancers, received adjuvant chemoradiation therapy after
curative surgery. Treatments such as adjuvant chemoradiation may
change the impact of IGFBP-3 methylation on survival of early-stage
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patients with IB/II gastric cancer was about 80%. Therefore, the
impact of IGFBP-3methylation on survival may have been diluted by
good survival outcomes in the analyzed patients.
The most interesting finding of this study was that women, but not
men, showed a trend toward poorer prognosis for DFS and OS in the
subset of patients with IGFBP-3 methylation as compared with those
without IGFBP-3 methylation. This observation may be caused by a
difference in IGFBP-3 values according to sex. Lin et al. reported that
women had significantly higher IGFBP-3 values than men and that
women older than 50 years showed a significant reduction in IGF-I/
IGFBP-3 molar ratio. Thus, IGFBP-3 methylation may have a more
powerful influence on survival outcomes in female thanmale patients [30].
Previous studies have shown that the transcriptional activity of the
methylated IGFBP-3 promoter is restored by treatment with the
demethylating agent 5’-aza-dC in some human cancers, including
hepatocellular carcinoma and non–small cell lung cancer [16,17].
However, 5’-aza-dC treatment restores IGFBP-3 expression in only a
portion of those cancer cell lines in which the promoter is methylated
[17]. These findings suggest that the mechanisms regulating
IGFBP-3 expression in human cancer cells are diverse and complex.
Thus, the multifaceted nature of the processes involved in the
regulation of IGFBP-3 expression might affect the results of our
study. Future research will investigate other mechanisms related to
IGFBP-3 expression and silencing in gastric cancer.
The mechanisms of IGFBP-3 expression and silencing in gastric
cancer have not been fully elucidated. However the status of IGFBP-3
methylation as measured by MS-PCR may be good predictive factor
for survival in specific subgroups of patients with early-stage gastric
cancer undergoing curative surgery. Further research is needed to
better understand the role of IGFBP-3 in gastric cancer.
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